Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$5.82
EPS est.
$6.73
EPS surprise
-13.57%
1-day move
+4.29%
United Therapeutics reported earnings that fell short of expectations on EPS, which typically raises concerns among investors. However, the stock reacted positively, increasing by 4.29%. This could indicate that investors are optimistic about other aspects of the company's performance or future potential despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.82 | $6.87 | -13.57% |
| Revenue | N/A | $797M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
United Therapeutics Corporation is a biotechnology company focused on developing innovative therapies for patients with chronic and life-threatening conditions. With a market cap of $25 billion, it plays a significant role in the health care sector, particularly in treating pulmonary arterial hypertension and other serious diseases.
Last quarter
In the last quarter, United Therapeutics reported an EPS of $7.70, exceeding expectations by 13.5%. The stock reacted positively, gaining over 13% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+1.88%
Avg 1-day reaction
+1.77%
Analysts are generally optimistic about United Therapeutics' upcoming earnings, expecting it to meet or exceed EPS and revenue estimates. The company has a strong track record of beating earnings expectations.
Bull case
If United Therapeutics can deliver an EPS above the consensus of $6.87, it may signal strong demand for its products and effective cost management, leading to a positive stock reaction.
Bear case
Conversely, if the company misses its EPS target, it could raise concerns about its growth prospects and operational challenges, potentially leading to a negative stock reaction.
Key metrics to watch
EPS
$6.87Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$797MRevenue growth is crucial for understanding the company's market performance and demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $6.87?
A beat on EPS could reinforce investor confidence in the company's growth trajectory and operational efficiency.
Q2
What are the revenue expectations for the upcoming quarter?
Revenue performance will indicate market demand for United Therapeutics' products and overall business health.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for United Therapeutics to exceed EPS expectations due to strong demand for its existing therapies.
Supporting evidence
The company has consistently beaten EPS estimates in the past, with a 75% success rate.
Recent positive trends in the biotechnology sector may not be fully reflected in current estimates.
Key risk
If revenue comes in significantly below $797M, it could undermine confidence in the company's growth prospects.
Pre-commit to what would confirm each case.
This quarter, the focus is on whether United Therapeutics can maintain its strong earnings trajectory amid competitive pressures.
Bull confirmed if
An EPS of $7.00 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $6.50 would raise concerns about growth and profitability.
What the market is pricing for the move.
Implied Move
±5.84%
Historical Avg
±5.8%
The options market is pricing in a potential stock movement of about 5.84%, indicating some uncertainty around the earnings report.
Options are pricing ±8.8% while UTHR has averaged ±5.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
41.2%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$48.8M
93,800 sh
2 insiders
Net
$48.8M
Net selling
Most Active Insiders· 158 open-market trades
$44.1M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
99.99%
of float
Insider
2.00%
of float
Holders
1,210
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
5,294,529 sh · $2.9B
12.34%
-1.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If United Therapeutics beats expectations, history suggests the stock could rise by about 4% to 5%, confirming strong demand and effective management.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss on earnings could lead to a decline of around 6% based on historical patterns, signaling potential issues in the company's operations.
The lines on the call that would change the story.
$4.7M
Net selling
Recent Transactions
Sep 25, 2026 · @ $476.13
2,744 sh
$1.3M
Sep 24, 2026 · @ $470.63
2,603 sh
$1.2M
Oct 6, 2026 · @ $540.68
2,054 sh
$1.1M
Sep 29, 2026 · @ $478.10
2,309 sh
$1.1M
Sep 24, 2026 · @ $471.77
2,160 sh
$1.0M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Avoro Capital Advisors LLC
2,777,777 sh · $1.5B
6.48%
5.6%
Vanguard Portfolio Management LLC
1,919,429 sh · $1.0B
4.48%
-4.2%
Vanguard Capital Management LLC
1,918,256 sh · $1.0B
4.47%
-2.0%
State Street Corporation
1,898,064 sh · $1.0B
4.43%
2.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.